Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AbbVie

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Benzinga

Keep AbbVie Stock On Your Watch List Ahead Of Earnings

AbbVie is within striking distance of a buy zone ahead of its next quarterly earnings report, expected on or around Jul. 29.

Investors Business Daily

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap of Monday's Biotech Catalysts - End of the Day Summary

Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.

Benzinga

Dow Jones Giant UnitedHealth Breaks Out, Leading 5 Stocks To Watch

Dow Jones stock UnitedHealth and AbbVie boast favorable tailwinds. They lead this week's top stocks to watch.

Investors Business Daily

AbbVie Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 10 strange trades.

Benzinga

Less talk, more action needed to reform IP for all

IP laws are supposed to work to aid pharmaceutical innovation in rich nations. Can a new system support treating illnesses rife in developing economies, too?

360info

Read news from The Economist, FT, and more,
with one subscription

Benzinga Before The Bell: Elon Musk's Kids, Apple's Potential Security Measure, Covid-19 Vaccine Wastage And Other Top Financial Stories Thursday, July 7

CNBC

Benzinga

4 High-Dividend Stocks Rise In Face Of Recession Freak-Out

Think you can avoid the S&P 500's pain with high-dividend and energy stocks? It's not working anymore, for most stocks.

Investors Business Daily

Vertex, WWE, KO Stock Among 25 Names On IBD Breakout Stocks Index

As the market regroups, 25 names — including Vertex, WWE, Li Auto and KO stock — make the IBD Breakout Stocks Index.

Investors Business Daily

5 NYSE Stocks To Watch And Buy: Here Are Fundamental And Technical Reasons Why

DECK is getting closer to the top of its large cup base.

Investors Business Daily

Check Out What Whales Are Doing With ABBV

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Analyzing AbbVie's Short Interest

AbbVie's (NYSE:ABBV) short percent of float has risen 27.78% since its last report. The company recently reported that it has 13.52 million shares sold short, which is 0.92% of all regular shares that are available for trading.

Benzinga

If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 6.01% on an annualized basis producing an average annual return of 15.88%. Currently, AbbVie has a market capitalization of $267.24 billion.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

AbbVie Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Recap of Tuesday's Biotech Catalysts - End of the Day Summary

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Ionis shares are trading low 4 percent at $35.10 in the after-hours session

Benzinga

Why AbbVie Stock Is Trading Higher Today

AbbVie Inc (NYSE: ABBV) shares are trading higher Tuesday after the company announced it submitted a supplemental New Drug Application for atogepant to the U.S. Food and Drug Administration to support the preventive treatment of chronic migraine in adults.

Benzinga

AbbVie Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 29 strange trades.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

AbbVie Whale Trades For June 14

Benzinga

AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial

AbbVie Inc (NYSE:ABBV) announced primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE NHL-1 phase 2 trial of epcoritamab. Epcoritamab demonstrated efficacy with durable responses in patients who had previously received at least two prior lines of anti-lymphoma therapy. The study cohort, which included 157 relapsed/refractory LBCL patients, demonstrated…

Benzinga

If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.42% on an annualized basis producing an average annual return of 16.4%. Currently, AbbVie has a market capitalization of $263.04 billion.

The Conversation

You no longer need surgery to be diagnosed with endometriosis. Here's what's changed

By age 44, endometriosis affects around one in nine women and people assigned female at birth in Australia.

Benzinga

AbbVie Whale Trades For June 01

A whale with a lot of money to spend has taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 10 strange trades.

Tribune News Service

Supreme Court leak prompts investors to press companies on abortion

WASHINGTON — Activist shareholders, seeking to galvanize support following a leaked Supreme Court draft opinion indicating that justices are poised to overturn Roe v. Wade, are pressing companies to explicitly explain how they will support their workers’ access to abortion and reproductive health services.

Roll Call

SCOTUS leak prompts investors to press companies on abortion - Roll Call

Activist shareholders are pressuring companies on access to abortion after a leaked draft Supreme Court opinion.

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Intellectual Property

Amyotrophic lateral sclerosis

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.